PRIMARY BILIARY CHOLANGITIS
Clinical trials for PRIMARY BILIARY CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY BILIARY CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY BILIARY CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Hard-to-Treat liver disease
Disease control Recruiting nowThis study is for adults with primary biliary cholangitis (PBC) and compensated cirrhosis who still have high alkaline phosphatase levels despite taking ursodeoxycholic acid (UDCA). Researchers want to see if adding fenofibrate to UDCA can normalize liver enzyme levels and improv…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE2, PHASE3 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated May 17, 2026 02:26 UTC
-
New hope for liver disease patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called CS0159 for people with primary biliary cholangitis (PBC), a chronic liver disease. It is for adults whose condition did not improve enough with or who cannot take the usual medicine, UDCA. About 135 participants will receive either CS0159 or a p…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug could extend life for those with bile duct disease and cirrhosis
Disease control Recruiting nowThis study tests a drug called seladelpar in 318 adults with primary biliary cholangitis (PBC) and compensated cirrhosis. The goal is to see if it can prevent serious events like death, liver transplant, or complications from liver disease. Participants will receive either the dr…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug for rare liver disease tested in real-world setting
Disease control Recruiting nowThis study follows about 424 people with primary biliary cholangitis (PBC), a rare liver disease, who are taking the drug elafibranor. Researchers want to see how well the drug controls the disease and its symptoms over 5 years in everyday medical practice. The goal is to check i…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: Ipsen • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug combo could help PBC patients who Don't respond to standard care
Disease control Recruiting nowThis study tests whether adding fenofibrate to the standard drug ursodeoxycholic acid (UDCA) helps people with primary biliary cholangitis (PBC) who do not get enough benefit from UDCA alone. About 150 adults with PBC will receive either the combination or a placebo for up to 36 …
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New hope for PBC patients: drug targets debilitating itch
Symptom relief Recruiting nowThis study tests an experimental drug called volixibat to see if it can reduce the intense itching caused by primary biliary cholangitis (PBC). About 260 adults with PBC and moderate-to-severe itching will receive either volixibat or a placebo. The main goal is to measure changes…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
Blood test levels after PBC treatment may predict survival, study finds
Knowledge-focused Recruiting nowThis study looks at 3,000 adults with primary biliary cholangitis (PBC) to see how changes in a key blood marker (alkaline phosphatase) after treatment relate to their risk of liver complications or death. Researchers aim to build a model that predicts survival without major live…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 02:37 UTC